TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9156955
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR (20 mg, twice daily)
Study: 18665761
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) 20 min a day with a 5‐mW soft laser for 6 months
Study: 18665761
Drug: Betahistine 16
Normalized name: betahistine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 16 mg twice a day for 6 months
Study: 8441234
Drug: rhIGF-I, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-I, 60 micrograms/kg, subcutaneous injections, administered at 0800, 1400, and 2000 hours for 5.5 days
Study: 28870129
Drug: Volar plating
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar plating (surgical treatment)
Study: 28870129
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (casting)
Study: 25741871
Drug: PictureRx illustrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PictureRx illustrated medication list
Study: 25741871
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (written list of medications in preferred language, with indication but no images)
Study: 22237419
Drug: sifilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifilcon A penetrated hydrogel lenses (Dk/t ± 117) worn on a daily basis for 9 months
Study: 20837741
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant overdenture (OD)
Study: 18498682
Drug: Chunghyul-dan 600
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chunghyul-dan 600 mg a day
Study: 10081854
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection plus 100 mg. epirubicin
Study: 7498868
Drug: 100 to
Normalized name: Zionodil 100 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 to 120 mg of hypericum extract bid
Study: 2206813
Drug: Ceftizoxime (intramuscular)
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftizoxime (intramuscular)
Study: 2206813
Drug: Amoxycillin (oral)
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin (oral)
Study: 7002569
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg/day by mouth, in three divided doses
Study: 31066232
Drug: Sodium tanshinone
Normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium tanshinone IIA sulfonate (STS) 80 mg qd for 7 days
Study: 30214156
Drug: Asenapine 1-10
Normalized name: asenapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 1-10 mg twice daily for up to 12 days
Study: 30214156
Drug: Asenapine 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 2.5-10 mg twice daily for up to 8 weeks
Study: 27810972
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) - 2 doses (1 g/kg/dose)
Study: 22290978
Drug: Asunaprevir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunaprevir (200 to 600 mg twice daily)
Study: 16250190
Drug: Augmented exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented exercise therapy time as Arm BASIS training (n=20)
Study: 16250190
Drug: Augmented exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented exercise therapy time as Bobath therapy (n=20)
Study: 16250190
Drug: No augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmented exercise therapy time (n=20)
Study: 16250190
Drug: Augmented exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented exercise therapy time as Arm BASIS training
Study: 16250190
Drug: Augmented exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented exercise therapy time as Bobath therapy
Study: 11872999
Drug: Triple-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug regimen (ZDV + 3TC + IDV)
Study: 11872999
Drug: Reinitiating either
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinitiating either the original triple-drug regimen or a new combination of nucleoside analogue reverse transcriptase inhibitors and protease inhibitors
Study: 10666558
Drug: 11 mg
Normalized name: benzocaine 11 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mg of midazolam
Study: 10666558
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of scopolamine
Study: 7834398
Drug: 300 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Study: 7834398
Drug: 300 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Study: 7834398
Drug: 1,000 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Study: 7834398
Drug: 1,000 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Study: 7834398
Drug: 3,000 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Study: 1964662
Drug: CY 216
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 216 (0.3 ml subcutaneous injections equivalent to 7,500 anti-Xa units)
Study: 1964662
Drug: Placebo (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.3 ml saline solution)
Study: 6155131
Drug: Pseudoephedrine 15
Normalized name: APAP 325/PSEUDOEPHEDRINE 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 15 mg
Study: 6155131
Drug: Pseudoephedrine 30
Normalized name: pseudoephedrine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 30 mg
Study: 31958446
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg orally on day 1 and then 80 mg orally on days 2 to 7 with physician's choice of antitussive
Study: 31958446
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of antitussive alone
Study: 29484635
Drug: Dipeptidyl Peptidase
Normalized name: Dipeptidyl peptidase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl Peptidase 1 Inhibitor AZD7986
Study: 26465781
Drug: OCTREE (intraportal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCTREE (intraportal chemotherapy plus mFOLFOX6)
Study: 26465781
Drug: mFOLFOX6 (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 (standard adjuvant chemotherapy)
Study: 20557366
Drug: 14-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Study: 20557366
Drug: 7-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Study: 18447631
Drug: GoChi (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoChi (120 mL/day)
Study: 16414904
Drug: Glycolic peeling
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycolic peeling and daily appliance of vitamin C
Study: 12878618
Drug: Remifentanil 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.08 micro g kg(‐1) min(‐1)
Study: 10762640
Drug: 5'‐DFUR (460
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR (460 mg/m2/day, daily, for two years)
Study: 10762640
Drug: 5‐FU (115
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (115 mg/m2/day, daily, for two years)
Study: 1634913
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 21 days
Study: 1634913
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 28 days
Study: 1634913
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 40 mg/m2 IV given weekly
Study: 1634913
Drug: Treatment assigned
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment assigned
Study: 30629473
Drug: MICRO (5-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: MICRO (5-min bouts of moderate-intensity physical activity performed hourly for nine consecutive hours over 4 days)
Study: 27601419
Drug: Bromelain (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain (pooled treatments)
Study: 1358498
Drug: Reduced glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glutathione (GSH) administration (1.2 g/day and 2.4 g/day intravenously)
Study: 1358498
Drug: Chlordiazepoxide (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (initial dose 75‐100 mg/day)
Study: 21076721
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin each night (Control group)
Study: 21076721
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin 12 h before PCI (Low-load group)
Study: 21076721
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin 2 h to 4 h before PCI (Mid-load group)
Study: 21076721
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg atorvastatin 2 h to 4 h before PCI (High-load group)
Study: 12459075
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg) with abciximab
Study: 12459075
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (70 U/kg) with abciximab
Study: 1932973
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/day, adjusted between 5 and 40 mg)
Study: 1932973
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/day, adjusted between 25 and 100 mg)
Study: 6660928
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (10 mg daily for 10 days, four times a year)
Study: 6660928
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50 mg for 10 days, four times a year)
Study: 22169947
Drug: Yohimbine HCl
Normalized name: yohimbine HCl
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine HCl (α(2)‐adrenergic receptor antagonist) administered 30 min before acquisition
Study: 22169947
Drug: Propranolol HCl
Normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol HCl (β‐adrenergic receptor antagonist) administered 90 min before selective reactivation
Study: 22169947
Drug: Propranolol HCl
Normalized name: propranolol HCl
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol HCl administered after reactivation of the memory
Study: 8568287
Drug: bivalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent live attenuated influenza A virus vaccine
Study: 7140133
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IV propranolol
Study: 7140133
Drug: 3.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg/kg oral propranolol
Study: 7140133
Drug: 0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg/kg IV timolol
Study: 7140133
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg oral timolol
Study: 14646609
Drug: Idazoxan (alpha-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (alpha-2 adrenoreceptor antagonist)
Study: 10383505
Drug: MK‐0966 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0966 250 mg q.d.
Study: 10383505
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg t.d.s.
Study: 10383505
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg q.d.s.
Study: 8678131
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg per day and medroxyprogesterone 2.5 mg per day
Study: 30037045
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of mixed spices
Study: 30037045
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of mixed spices
Study: 359255
Drug: Difunisal (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difunisal (250 mg or 500 mg twice daily for 5 days)
Study: 359255
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg four times daily for 5 days)
Study: 31542737
Drug: Plan Well
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plan Well Guide decision aid administered to the patient by a facilitator with the SDM present.
Study: 25577661
Drug: Consistent limb
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent limb group (DTaP-IPV-Hib and PCV13 administered to the right leg)
Study: 25577661
Drug: Alternating limb
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating limb group (DTaP-IPV-Hib and PCV13 administered to alternating limbs)
Study: 21292088
Drug: MSBR +
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSBR + HGF (intravenous 150 μg/kg per day)
Study: 17919488
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g oleic acid (FFA, 1830 kJ)
Study: 17919488
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g macadamia oil (TG, 1856 kJ)
Study: 17919488
Drug: 600 mL
Normalized name: urinary bag 600 mL-10" MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mL 4% milk protein (control, 352 kJ)
Study: 15490072
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy at a dose of 0.25 U/kg body weight/week for 72 months
Study: 11876011
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, aqueous nasal spray, 400 micrograms per day, administered every 12 hours for 6 weeks
Study: 8042862
Drug: Topical Acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Acyclovir (ACV) plus 348U87, initiated immediately after UV exposure
Study: 2665093
Drug: Conservative-functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative-functional treatment with a newly developed shoe
Study: 798654
Drug: Daily occlusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily occlusive applications of butylated hydroxytoluene for 60 days
Study: 31324213
Drug: Supraglottic airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraglottic airway device (i-gel®)
Study: 29190604
Drug: Mulberry extract
Normalized name: MULBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry extract (300 mg/d, twice per day for 12 weeks)
Study: 22088586
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (Acupuncture + Plantain and Senna Granule)
Study: 19318652
Drug: Assistance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistance with pain treatment intervention
Study: 17538804
Drug: Cetaphil Moisturizing
Normalized name: Cetaphil Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetaphil Moisturizing Cream applied twice daily for 15 days on one half of the face
Study: 12609480
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (4 matched postmenopausal women without MPA treatment)
Study: 8622116
Drug: Isepamicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin (15 mg/kg or 8 mg/kg once daily; 7.5 mg/kg twice daily; 4 mg/kg twice daily)
Study: 6218099
Drug: Mezlocillin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (16 g daily)
Study: 6218099
Drug: Carbenicillin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin (30 g daily)
Study: 26923301
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood infusion set (control)
Study: 8547209
Drug: Ramipril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (mean dose 8 mg)
Study: 7048826
Drug: Urokinase (200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (200,000 Ploug units during the first 24 hours) followed by heparin (40,000 units daily for 5 days)
Study: 7048826
Drug: Heparin (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (40,000 units daily for 6 days)
Study: 28205258
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride 200 mg IV
Study: 26637583
Drug: 100 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg/mL of AMB nasal irrigation daily for 2 months
Study: 26637583
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) solution nasal irrigation daily for 2 months
Study: 19474650
Drug: DRV/r (darunavir/ritonavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r (darunavir/ritonavir) 600/100 mg twice daily
Study: 12692749
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril, 20 mg o.d. for two years)
Study: 9888904
Drug: Teaching patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services (7 to 12 individual treatment sessions from a research psychologist plus routine care)
Study: 9888904
Drug: Teaching patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching patients to identify early symptoms of relapse and seek prompt treatment from health services
Study: 7741619
Drug: Control patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patch (not activated)
Study: 7102768
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral sulpiride for 4 days from the third postpartum day
Study: 8092084
Drug: 0.80 g
Normalized name: Niacinamide 0.80 g in 40 mL / Adenosine 0.01 g in 40 mL TOPICAL LIQUID [AAPE Continuous Renewal Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.80 g protein.kg‐1.d‐1
Study: 8092084
Drug: 1.62 g
Normalized name: Brioschi 1.8 GM / 1.62 GM Granules for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62 g protein.kg‐1.d‐1
Study: 12869382
Drug: Therapeutic infusions
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic infusions of immunoglobulins (Ig)
Study: 12869382
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro with RBC suspensions containing fibrinogen, albumin, and Ig
Study: 9094145
Drug: Selegiline (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (both doses)
Study: 3113244
Drug: misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 200 micrograms twice daily
Study: 29520867
Drug: Phenylephrine 50
Normalized name: phenylephrine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 50 μg
Study: 29520867
Drug: Ephedrine 4
Normalized name: ephedrine 48 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 4 mg
Study: 28794283
Drug: Proinsulin peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin peptide immunotherapy (intradermally every 2 or 4 weeks for 6 months)
Study: 9296310
Drug: Temocapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril (10-40 mg once daily)
Study: 9296310
Drug: Atenolol (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25-100 mg once daily)
Study: 7982016
Drug: Inosine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (1.5 g daily, 3 x 500 mg for 6 weeks)
Study: 3722507
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical minoxidil
Study: 3722507
Drug: 0.01% topical
Normalized name: Retin-A 0.01% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% topical minoxidil
Study: 30055593
Drug: Practicing self‐medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practicing self‐medication
Study: 24971565
Drug: Palivizumab prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab prophylaxis (6 consecutive monthly doses)
Study: 15930349
Drug: ABI-007 (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-007 (260 mg/m², 30 minutes; n = 14)
Study: 15930349
Drug: Taxol (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol (175 mg/m², 3 hours; n = 13)